CCRT with non-anthracycline chemotherapy for newly diagnosed localized ENKL
| Reference . | Study design . | Treatment . | RT delivery Median dose (range) . | No. of patients . | CR, % . | Median follow-up, mo (range) . | OS, % . | PFS, % . | Leukopenia grade 3, %/grade 4, % . | Mucositis* grade 3, %/grade 4, % . | Febrile neutropenia grade 3, %/grade 4, % . | Treatment-related death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simultaneous initiation of RT and chemotherapy | ||||||||||||
| 29,47 | Phase 1/2 | RT-2/3DeVIC: | 3D-CRT | 27 | 77 | 67 (61-94) | 70 (5 y) | 63 (5 y) | 85/15† | 30/0 | 15/0* | None |
| RT+ 2/3DeVIC ×3 | 50 Gy (50-50.4) | |||||||||||
| 41 | Phase 2 | DEP-CCRT/DVIP: | NA | 33 | 63 | 59 (16-79) | 66 (5 y) | 60 (5 y) | 35/48† | 30/0 | 35/0† | Pancreatitis (n = 1), |
| RT + DEP ×2 | 50.4 Gy | Infection (n = 1) | ||||||||||
| → DVIP ×2 | ||||||||||||
| 42 | Retrospective | RT + modified ESHAP ×2 → modified ESHAP ×2 | 3D-CRT (n = 10), | 13 | 92 | 38 (NA) | 72 (2 y) | 90 (2 y, FFP) | 31/62‡ | 23/23 | 54/15 | None |
| IMRT (n = 3) | ||||||||||||
| 40 Gy (40-52.2) | ||||||||||||
| CCRT with weekly cisplatin followed by non-anthracycline chemotherapy | ||||||||||||
| 43 | Phase 2 | CCRT-VIPD: | 3D-CRT | 30 | 80 | 24 (17-37) | 86 (3 y) | 85 (3 y) | 20/27† | 0/0§ | 50/10† | Infection (n = 2) |
| RT + wCDDP | 40 Gy (40-52.8) | |||||||||||
| → VIPD ×3 | ||||||||||||
| 30 | Phase 2 | CCRT-VIDL: | NA | 30 | 87 | 44 (95% CI, 41-47) | 73 (5 y) | 60 (5 y) | 20/60† | 13/3§ | 17/0† | None |
| RT + wCDDP | 40 Gy (40-50) | |||||||||||
| → VIDL ×2 (→ HD-AHSCT if NK-PI score 2-3) | ||||||||||||
| 44 | Phase 2 | CCRT-MIDLE: | 3D-CRT or IMRT | 28 | 82 | 46 (95% CI, 39-47) | 82 (3 y) | 74 (3 y) | 9/83 (n = 23)†,‡ | 4/0§ | 43/0† | Acute kidney injury and pneumonia (n = 1) |
| RT + wCDDP + triweekly l-asp → MIDLE ×2 | NA (36-44) | |||||||||||
| 45 | Phase 2 | RT + wCDDP | IMRT | 32 | 84 | 38 (NA) | 88 (3 y) | 84 (3 y) | (n = 7)/(n = 6)† | 0/0§ | (n = 16)/(n = 2)† | Infection (n = 1) |
| → GDP ×3 | 56 Gy (NA) | |||||||||||
| Reference . | Study design . | Treatment . | RT delivery Median dose (range) . | No. of patients . | CR, % . | Median follow-up, mo (range) . | OS, % . | PFS, % . | Leukopenia grade 3, %/grade 4, % . | Mucositis* grade 3, %/grade 4, % . | Febrile neutropenia grade 3, %/grade 4, % . | Treatment-related death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simultaneous initiation of RT and chemotherapy | ||||||||||||
| 29,47 | Phase 1/2 | RT-2/3DeVIC: | 3D-CRT | 27 | 77 | 67 (61-94) | 70 (5 y) | 63 (5 y) | 85/15† | 30/0 | 15/0* | None |
| RT+ 2/3DeVIC ×3 | 50 Gy (50-50.4) | |||||||||||
| 41 | Phase 2 | DEP-CCRT/DVIP: | NA | 33 | 63 | 59 (16-79) | 66 (5 y) | 60 (5 y) | 35/48† | 30/0 | 35/0† | Pancreatitis (n = 1), |
| RT + DEP ×2 | 50.4 Gy | Infection (n = 1) | ||||||||||
| → DVIP ×2 | ||||||||||||
| 42 | Retrospective | RT + modified ESHAP ×2 → modified ESHAP ×2 | 3D-CRT (n = 10), | 13 | 92 | 38 (NA) | 72 (2 y) | 90 (2 y, FFP) | 31/62‡ | 23/23 | 54/15 | None |
| IMRT (n = 3) | ||||||||||||
| 40 Gy (40-52.2) | ||||||||||||
| CCRT with weekly cisplatin followed by non-anthracycline chemotherapy | ||||||||||||
| 43 | Phase 2 | CCRT-VIPD: | 3D-CRT | 30 | 80 | 24 (17-37) | 86 (3 y) | 85 (3 y) | 20/27† | 0/0§ | 50/10† | Infection (n = 2) |
| RT + wCDDP | 40 Gy (40-52.8) | |||||||||||
| → VIPD ×3 | ||||||||||||
| 30 | Phase 2 | CCRT-VIDL: | NA | 30 | 87 | 44 (95% CI, 41-47) | 73 (5 y) | 60 (5 y) | 20/60† | 13/3§ | 17/0† | None |
| RT + wCDDP | 40 Gy (40-50) | |||||||||||
| → VIDL ×2 (→ HD-AHSCT if NK-PI score 2-3) | ||||||||||||
| 44 | Phase 2 | CCRT-MIDLE: | 3D-CRT or IMRT | 28 | 82 | 46 (95% CI, 39-47) | 82 (3 y) | 74 (3 y) | 9/83 (n = 23)†,‡ | 4/0§ | 43/0† | Acute kidney injury and pneumonia (n = 1) |
| RT + wCDDP + triweekly l-asp → MIDLE ×2 | NA (36-44) | |||||||||||
| 45 | Phase 2 | RT + wCDDP | IMRT | 32 | 84 | 38 (NA) | 88 (3 y) | 84 (3 y) | (n = 7)/(n = 6)† | 0/0§ | (n = 16)/(n = 2)† | Infection (n = 1) |
| → GDP ×3 | 56 Gy (NA) | |||||||||||